ABL1 and lymphoid neoplasm: Based on findings from the literature and in accordance with the “World Health Organization 5th edition classification of hematopoietic and lymphoid tumors” and “the 2022 International Consensus Classification,” the diagnosis was revised to “myeloid/lymphoid neoplasm with ETV6::ABL1 fusion(M/LN-ETV6::ABL1).” Following treatment, the patient's fatigue significantly improved, and the fusion gene became undetectable.